Hepatitis B Virus Antisense Oligonucleotide AHB-137 clinical trials
Also written AHB-137.
How each study uses Hepatitis B Virus Antisense Oligonucleotide AHB-137 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Hepatitis B Virus Antisense Oligonucleotide AHB-137 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Ausper Biopharma Co., Ltd. (8) · AusperBio Therapeutics Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test Hepatitis B Virus Antisense Oligonucleotide AHB-137, phase 3 first.
- Dec 2026Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)Phase 3 · Ausper Biopharma Co., Ltd.
- Dec 2026A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)Phase 2 · Ausper Biopharma Co., Ltd.
- May 2027Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsPhase 2 · AusperBio Therapeutics Inc.
- Jun 2027A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis BPhase 2 · Ausper Biopharma Co., Ltd.
- Jul 2027A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B DrugsPhase 2 · Ausper Biopharma Co., Ltd.
- Jul 2027A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)Phase 2 · Ausper Biopharma Co., Ltd.
Studies
Open first, then newest update. How each study uses Hepatitis B Virus Antisense Oligonucleotide AHB-137 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruitingPhase 2AusperBio Therapeutics Inc.NCT07654283Written as AHB-137
- Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific RegionRecruitingPhase 2AusperBio Therapeutics Inc.NCT07370207Written as AHB-137
- A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)RecruitingPhase 2Ausper Biopharma Co., Ltd.NCT07137910Written as AHB-137
- A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.RecruitingPhase 1Ausper Biopharma Co., Ltd.NCT07600788Written as AHB-137 injection
- A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B DrugsRecruitingPhase 2Ausper Biopharma Co., Ltd.NCT07069569Written as AHB-137
- A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis BRecruitingPhase 2Ausper Biopharma Co., Ltd.NCT07635186Written as AHB-137
- Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).CompletedPhase 2Ausper Biopharma Co., Ltd.NCT06550128Written as AHB-137 (24 weeks)
- A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)Active, not recruitingPhase 2Ausper Biopharma Co., Ltd.NCT06993480Written as AHB-137
- A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) PatientsCompletedPhase 1/2Ausper Biopharma Co., Ltd.NCT06115993Written as AHB-137 injection
- Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)Active, not recruitingPhase 3Ausper Biopharma Co., Ltd.NCT07246889Written as AHB-137
- A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis BCompletedPhase 1AusperBio Therapeutics Inc.NCT05717686Written as AHB-137 injection
Given beside what is tested · 3 — Hepatitis B Virus Antisense Oligonucleotide AHB-137 is usual care or a partner of the new treatment
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Not yet recruitingPhase 1/2Grand Theravac Life Sciences (Hangzhou) Co., Ltd.NCT07897448Written as AHB-137
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Not yet recruitingPhase 1/2Ausper Biopharma Co., Ltd.NCT07876856Written as AHB-137
- Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)Active, not recruitingPhase 2Ausper Biopharma Co., Ltd.NCT06829329Written as AHB-137